RxDoctor Payments Data

Michael Allen, PA

Physician Assistant · Danville, KYNPI 1376026252

Payments from drug & device makers

$2,308in general payments, 2019–2025

Across 156 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$967
  • AstraZeneca$441
  • Amgen$214
  • Vanda Pharmaceuticals Inc.$204
  • GSK$166
  • Astellas Pharma US Inc$98
  • plus $220 from 8 others

What the payments were for

  • Food & beverage$2,22396%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,308 in reported general payments places this provider in the 80th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$5,236
Medicare patients
109
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate74$70,242
MounjaroTirzepatide65$67,803
OzempicSemaglutide59$62,373
JardianceEmpagliflozin63$52,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$50,521
EliquisApixaban66$43,997
Invega SustennaPaliperidone Palmitate12$40,946
Tresiba Flextouch U-200Insulin Degludec28$28,469
FarxigaDapagliflozin Propanediol40$26,060
LinzessLinaclotide24$22,212
TrulicityDulaglutide16$20,049
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$18,628
QuliptaAtogepant15$15,331
XareltoRivaroxaban11$15,094
TradjentaLinagliptin13$13,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$29$87,85281 claims
Novo NordiskOzempic, Rybelsus$36$73,51971 claims
Boehringer IngelheimJardiance, Tradjenta$56$66,41576 claims
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$441$51,93982 claims
PfizerEliquis, Lyrica$17$51,55178 claims
GSKTrelegy Ellipta$166$50,52180 claims
AbbVieLinzess, Qulipta, Synthroid$967$39,76874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →